BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32362604)

  • 1. Clinical profile, cytogenetics and treatment outcomes of adult acute myeloid leukemia.
    Namratha Udupa MS; Babu KG; Suresh Babu MC; Lakshmaiah KC; Lokanatha D; Jacob AL; Lokesh KN; Rajeev LK; Rudresh AH; Devi L
    J Cancer Res Ther; 2020; 16(1):18-22. PubMed ID: 32362604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
    Haferlach T; Schoch C; Löffler H; Gassmann W; Kern W; Schnittger S; Fonatsch C; Ludwig WD; Wuchter C; Schlegelberger B; Staib P; Reichle A; Kubica U; Eimermacher H; Balleisen L; Grüneisen A; Haase D; Aul C; Karow J; Lengfelder E; Wörmann B; Heinecke A; Sauerland MC; Büchner T; Hiddemann W
    J Clin Oncol; 2003 Jan; 21(2):256-65. PubMed ID: 12525517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
    Leith CP; Kopecky KJ; Godwin J; McConnell T; Slovak ML; Chen IM; Head DR; Appelbaum FR; Willman CL
    Blood; 1997 May; 89(9):3323-9. PubMed ID: 9129038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization.
    Klaus M; Haferlach T; Schnittger S; Kern W; Hiddemann W; Schoch C
    Cancer Genet Cytogenet; 2004 Nov; 155(1):47-56. PubMed ID: 15527902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia.
    Strati P; Daver N; Ravandi F; Pemmaraju N; Pierce S; Garcia-Manero G; Nazha A; Kadia T; Jabbour E; Borthakur G; Faderl S; Quintas-Cardama A; Kantarjian H; Cortes J
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S276-81. PubMed ID: 23969309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
    J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.
    Wuchter C; Karawajew L; Ruppert V; Büchner T; Schoch C; Haferlach T; Ratei R; Dörken B; Ludwig WD
    Leukemia; 1999 Dec; 13(12):1943-53. PubMed ID: 10602414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Parameters of Acute Myeloid Leukaemia at Presentation.
    Jahic A; Iljazovic E; Hasic S; Arnautovic AC; Sabitovic D; Mesanovic S; Sahovic H; Simendic V
    Med Arch; 2017 Feb; 71(1):20-24. PubMed ID: 28428668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and pattern of chromosomal abnormalities in acute myeloid leukemia from Western India: A retrospective study.
    Vundinti BR; Korgaonkar S; Dhangar S; Jijina F; Shanmukhaiah C
    J Cancer Res Ther; 2023; 19(2):340-346. PubMed ID: 37006070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups.
    Creutzig U; Zimmermann M; Reinhardt D; Rasche M; von Neuhoff C; Alpermann T; Dworzak M; Perglerová K; Zemanova Z; Tchinda J; Bradtke J; Thiede C; Haferlach C
    Cancer; 2016 Dec; 122(24):3821-3830. PubMed ID: 27529519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical and cytogenetics studies on acute myeloid leukemia with abnormality of chromosome 11].
    Lu Y; Xu W; Chen Z; Lou J; Jin J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Oct; 25(5):583-5. PubMed ID: 18841578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China.
    Zheng J; Wang X; Hu Y; Yang J; Liu J; He Y; Gong Q; Yao J; Li X; Du W; Huang S
    Cytometry B Clin Cytom; 2008 Jan; 74(1):25-9. PubMed ID: 18061959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.
    Hu XM; Liu F; Zheng CM; Li L; Liu C; Zhang SS; Xiao HY; Yang XH; Wang HZ; Xu YG; Hu NP; Ma R
    Chin J Integr Med; 2009 Jun; 15(3):193-7. PubMed ID: 19568712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment.
    Nachar VR; Perissinotti AJ; Scappaticci GB; Bixby DL; Marini BL
    Leuk Res; 2017 Dec; 63():56-61. PubMed ID: 29102597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
    Grimwade D; Walker H; Oliver F; Wheatley K; Harrison C; Harrison G; Rees J; Hann I; Stevens R; Burnett A; Goldstone A
    Blood; 1998 Oct; 92(7):2322-33. PubMed ID: 9746770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia.
    Lazarevic V; Hörstedt AS; Johansson B; Antunovic P; Billström R; Derolf Å; Lehmann S; Möllgård L; Peterson S; Stockelberg D; Uggla B; Vennström L; Wahlin A; Höglund M; Juliusson G
    Eur J Haematol; 2015 May; 94(5):419-23. PubMed ID: 25200361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of cytogenetic abnormalities in acute myeloid leukaemia.
    Harani MS; Adil SN; Kakepoto GN; Khilji Z; Shaikh U; Khurshid M
    J Pak Med Assoc; 2006 Jan; 56(1):9-13. PubMed ID: 16454127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological characteristics, cytogenetic profile, and outcome of RUNX1-RUNX1T1-positive acute myeloid leukemia: Experience of an Indian tertiary care center.
    Gupta R; Yadav S; Parashar Y; Rahman K; Singh MK; Chandra D; Gupta A; Nityanand S
    Int J Lab Hematol; 2020 Feb; 42(1):37-45. PubMed ID: 31725954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.